# Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

> **NCT04730583** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 34 (actual)

## Conditions studied

- Cutaneous Neurofibroma

## Interventions

- **DRUG:** Kybella
- **DEVICE:** 1064nm laser
- **DEVICE:** 755nm Alexandrite Laser

## Key facts

- **NCT ID:** NCT04730583
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-02
- **Primary completion:** 2024-04-19
- **Final completion:** 2024-04-19
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04730583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04730583, "Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04730583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*